Phase II of Oral Satraplatin in Patients With Metastatic Breast Cancer (MBC)
This is a Phase II open label, nonrandomized study for patients with metastatic breast
cancer.
WHAT IS SATRAPLATIN:
Satraplatin is a member of the platinum-based class of chemotherapy drugs. Platinum-based
drugs have been clinically proven to be one of the most effective classes of anticancer
therapies. Unlike the currently marketed platinum-based drugs, satraplatin can be given
orally.
Interventional
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
To determine the objective response rate (ORR) of oral satraplatin in patients with metastatic breast cancer
1 year
Yes
Joyce O'Shaughnessy, MD
Principal Investigator
US Oncology
United States: Food and Drug Administration
Protocol 05-021
NCT00265655
November 2005
February 2008
Name | Location |
---|---|
US Oncology | Houston, Texas 77060 |